Article
Treatment with dasatinib or nilotinib in chronic myeloid leukemia patients who failed to respond to two previously administered tyrosine kinase inhibitors--a single center experience.
Clinics (Sao Paulo, Brazil) - 1 Aug 2015
Ribeiro Beatriz Felicio, Miranda Eliana C M, Albuquerque Dulcinéia Martins de, Delamain Márcia T, Oliveira-Duarte Gislaine, Almeida Maria Helena, Vergílio Bruna, Silveira Rosana Antunes da, Oliveira-Duarte Vagner, Lorand-Metze Irene, De Souza Carmino A, Pagnano Katia B B
Abstract excerpt
OBJECTIVE: To evaluate hematological, cytogenetic and molecular responses as well as the overall, progression-free and event-free survivals of chronic myeloid leukemia patients treated with a third tyrosine kinase inhibitor after failing to respond to imatinib and nilotinib/dasatinib. METHODS: Bone marrow karyotyping and real-time quantitative polymerase chain reaction were performed at baseline and at 3, 6, 12...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.